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Abstract
Germline inactivating mutations in BRCA1 and BRCA2 genes are responsible for Hereditary Breast and Ovarian Cancer
Syndrome (HBOCS). Genetic testing of these genes is available, although approximately 15% of tests identify variants of
uncertain significance (VUS). Classification of these variants into pathogenic or non-pathogenic type is an important
challenge in genetic diagnosis and counseling. The aim of the present study is to functionally assess a set of 7 missense VUS
(Q1409L, S1473P, E1586G, R1589H, Y1703S, W1718L and G1770V) located in the C-terminal region of BRCA1 by combining
in silico prediction tools and structural analysis with a transcription activation (TA) assay. The in silico prediction programs
gave discrepant results making its interpretation difficult. Structural analysis of the three variants located in the BRCT
domains (Y1703S, W1718L and G1770V) reveals significant alterations of BRCT structure. The TA assay shows that variants
Y1703S, W1718L and G1770V dramatically compromise the transcriptional activity of BRCA1, while variants Q1409L, S1473P,
E1586G and R1589H behave like wild-type BRCA1. In conclusion, our results suggest that variants Y1703S, W1718L and
G1770V can be classified as likely pathogenic BRCA1 mutations.
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Introduction
Between 10 and 20% of the breast cancer cases appearing in the
general population present familial history of the disease [1].
Mutations in BRCA1 and BRCA2 genes confer high lifetime risks of
breast and ovarian cancer, among other neoplasias [2,3].
Inactivating germline mutations in these genes account for 20–
50% of familial cases, depending on the population [4]. Thus,
genetic analysis of BRCA1 and BRCA2 is a cornerstone of genetic
counseling practice. However, classification of genetic variants as
pathogenic is challenging, particularly for missense changes and
for silent or intronic variants that cannot be directly associated
with increased cancer risk and are classified as variants of
uncertain significance (VUS), which are found in 13% of BRCA1
and BRCA2 genetic tests [5]. Diverse multifactorial likelihood
algorithms have been developed and applied for both BRCA1 and
BRCA2 variants (reviewed in Spurdle et al., 2011) [6]. These
models use the combination of a number of independent features
(sequence conservation, type of amino-acid change, familial co-
segregation, family and personal cancer history, tumor data, co-
occurrence with a deleterious mutation, and severity of amino acid
change) to establish the likelihood that a given VUS is pathogenic
or non-pathogenic. In many cases there is not enough data to
classify such mutations for clinical purposes. Therefore, functional
analyses that assess specific properties of BRCA1 or BRCA2 may
help to classify VUS [7]. In particular, BRCA1 encodes for a
protein of 1,863 amino acids and with multiple functional domains
[8]. Several functional assays have been conducted to evaluate
VUS in BRCA1 at the level of its global and domain-based
functions, including ubiquitin ligase activity assays, protease
sensitivity assays, phosphopeptide binding assays, small colony
phenotype assays, yeast localization phenotype assays, and
embryonic stem cell-based functional assays (review in Millot
et al., 2012) [9]. In the work presented here, we combine a
functional assay - the transcription activation (TA) assay, which is
based on the function of the BRCA1 carboxy-terminal region (aa
1396–1863) in transcriptional activation domain when linked to a
sequence-specific DNA binding module - [10] with protein
structural analyses [11] to assess the functional impact of seven
BRCA1 C-terminal VUS. Our results indicate that three of them
(Y1703S, W1718L, G1770V) have significant functional impact
and may represent pathogenic BRCA1 variants while the
remaining four do not have a functional impact.
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Materials and Methods
BRCA1 VUS
Seven missense BRCA1 C-terminal variants (Q1409L, S1473P,
E1586G, R1589H, Y1703S, W1718L and G1770V), identified
through genetic testing of patients with suspicion of Hereditary
Breast and Ovarian Cancer Syndrome (HBOCS) as part of the
Hereditary Cancer Program of the Catalan Institute of Oncology,
were included in this study (Figure 1). Written informed consent
was obtained from all subjects. The study received the approval of
the Ethics Committee of IDIBELL. The pedigrees of these families
are depicted in Figure S1. BRCA1 and BRCA2 genetic analyses
consisted of screening of point mutations and large genomic
rearrangements [12]. Genetic tests were carried out once patients
had received appropriate genetic counseling and provided written
informed consent.
In Silico Predictions
The BRCA1 sequences containing the VUS were evaluated for
their potential pathogenicity using the following algorithms: Align-
GVGD [13], PolyPhen-2 [14], SIFT [15], Mutation Assessor [16],
PhD-SNP [17], SNAP [18], I-Mutant [19], PON-P [20], and
Condel [21]. The Align-GVGD algorithm was used at two depths
of alignment (human to frog and human to sea urchin). The results
of PolyPhen-2 were retrieved from the original webpage (version
2.2.2) but also from version 2.0.22 run by PON-P and version 1
run by Condel, which use them for weighted average scores.
Transcription Activation Assay
The assay was based on the mammalian expression of the firefly
luciferase gene under the control of five GAL4 binding sites [10].
In this system, pcDNA3 constructs containing the GAL4 DNA
binding domain (DBD) fused to the wild-type or VUS-containing
BRCA1 C-terminal region were used. Pathogenic mutation
controls (M1775R and Y1853X) were included in the assays.
Constructs containing the VUS were generated by site-directed
mutagenesis using the QuickChange II Site-Directed Mutagenesis
Kit (Agilent Technologies, USA) and the wild-type sequence as a
template (U14680). Human embryonic kidney (HEK) 293T cells
were co-transfected (X-tremeGENE 9 DNA transfection Reagent,
Roche Applied Science, Mannheim, Germany) with the pcDNA3
construct encoding either the wild-type or the VUS sequence, the
pG5Luc plasmid that contains the luciferase reporter gene, and
the phRG-TK plasmid that contains a Renilla luciferase gene
under the control of a constitutive thymidine kinase promoter,
which acts as an internal control. Luciferase was quantified using
the Dual-Luciferase Reporter Assay System (Promega, Madison,
USA).
Protein Structural Rationalizations
To predict the impact of the VUS on both the folding and
phosphopeptide binding of the BRCT domains a structural
analysis was carried out by mapping the position of the variants
on the BRCA1 structures collected from the Protein Data Bank
[22] (PDB, www.pdb.org) and analyzing them manually with
Pymol (http://www.pymol.org). The structures were collected by
BLAST-querying the PDB using the BRCA1 sequence (UniProt
accession code P38398). Only the VUS mapped in the BRCT
tandem domains (Y1703S, W1718L and G1770V) were analyzed
using this approach, as there are no structural data for the
upstream domain or regions.
Results
In Silico Predictions
Several algorithms designed to predict deleterious versus neutral
missense changes were used (Table 1). Align-GVGD [13],
PolyPhen-2 [14], SIFT [15], Mutation Assessor [16], PhD-SNP
[17], SNAP [18] and I-Mutant [19] differ in the properties taken
into account to generate the prediction and in the method and
possible training for decision-making (reviewed in Thursberg,
et al., 2010) [23]. PON-P [20] integrates PolyPhen2, SIFT, PhD-
SNP, SNAP and I-Mutant using a random forest method, whereas
Condel integrates PolyPhen2, SIFT and Mutation Assessor using a
weighted average of the normalized scores of the individual
methods. Both integration methods claim to outperform individual
ones [20,21]. Table 1 shows the outcomes of all methods, for
comparison with high discrepancy between different programs.
The two integrative algorithms indicate that variants Q1409L,
S1473P, E1586G and R1589H have a benign effect and that
G1770V has a damaging effect, whereas they disagree in their
predictions for variants Y1703S and W1718L. Furthermore the
results of PON-P and Condel for Q1409L and G1770V strikingly
diverge from those of Align-GVGD, which classify Q1409L as
most likely to interfere with BRCA1 function and G1770V as less
likely using the alignment from human to frog. Also SIFT,
Figure 1. Illustration depicting the location of the C-terminal BRCA missense variants and negative controls. This Figure shows the
position of missense variants analyzed in the present study (black arrows) and the negative controls (closed gray arrows, underlined) within the
vector used in the TA experiments.
doi:10.1371/journal.pone.0061302.g001
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Mutation Assessor, PhD-SNP, SNAP and I-Mutant show diver-
gent tendencies.
Transcription Activation Assay
Using the transcriptional assay, three VUS (Y1703S, W1718L
and G1770V) showed a significant decrease in reporter expression
compared to wild-type BRCA1 (Figure 2). The luciferase activity of
these three mutants was very similar to that observed for the
known pathogenic mutants used as controls: that is ,5%,
compared to the wild-type construct. Conversely, the remaining
four VUS (Q1409L, S1473P, E1586G and R1589H) displayed
similar transcriptional activity to that of the wild-type construct.
Protein Structural Rationalizations
A structural analysis was performed for those VUS located in
the BRCT domains (Y1703S, W1718L and G1770V). Y1703 is
located at the BRCT dual-repeat-interaction interface (Figure 3A),
directed towards the linker. It forms a hydrogen bond with H1746
(Figure 3B). The change to a serine, by removal of the aromatic
ring, is likely to disrupt this bond and the surrounding
hydrophobic interactions and to affect the stability of the domain
and the dual-repeat interaction. It may also affect the peptide
binding through K1702 (Figure 3B), which interacts directly with
the peptide’s phosphoserine. W1718 is loosely packed in the core
of the BRCT-N domain and is part of a highly conserved motif















sea urchin Prob. Pred. Prob. Class Prob. Pred. Prob. Class
c.4226A.T Q1409L C65 C15 0.015 benign 0.995 Del. 0.007 benign 0.00 damaging
c.4417T.C S1473P C0 C0 0.004 benign 0.960 Del. 0.124 benign 0.01 damaging
c.4757A.G E1586G C0 C0 0.003 benign 0.995 Del. 0.124 benign 0.01 damaging
c.4766G.A R1589H C0 C0 0.000 benign 0.000 N 0.000 benign 1.00 tolerated
c.5108A.C Y1703S C65 C65 0.430 benign 1.000 Del. 0.689 Possib.
damaging
0.00 damaging
c.5153G.T W1718L C55 C55 0.086 benign 1.000 Del. 0.497 benign 0.00 damaging
c.5309G.T G1770V C0 C0 0.093 benign 0.999 Del. 0.964 possib.
damaging
0.00 damaging




Impact Pred. Reliability Pred. Accur. DDG Pred. Pred. Class Accur. Prob. Class
1.100 low N 3 N 60 0.22 N 0.14 N 0.84 0.000 N
0.975 low N 3 N 85 22.07 Dest 0.18 N 0.76 0.018 N
1.040 low N 8 P 58 21.81 Dest 0.12 N 0.84 0.014 N
21.040 neutral N 8 N 92 21.52 Dest 0.00 N 0.86 0.000 N
2.670 medium P 9 P 58 21.44 Dest 0.39 UV 0.60 0.746 Del
3.105 medium P 4 P 58 20.81 N 0.57 UV 0.46 0.065 N
2.135 medium P 8 P 78 21.20 Dest 0.98 P 0.96 0.906 Del
Each predictor yields its own type of results, usually quantitative and categorical. We have chosen the most representative of each.
1Predictors PON-P and Condel integrate results from other predictors run in their own servers; as PolyPhen-2 versions and their results differ if they are run in the
PolyPhen-2 website or the other 2, all of them are shown for comparison. 2Classification of variants in different classes according to Align-GVGD algorithm (Align-
Grantham Variation Grantham Deviation; http://agvgd.iarc.fr), C65 means ‘‘Most likely to interfere with function, C0 means ‘‘least likely’’ (possible classes are: C65.
C55.C45.C35.C25.C15.C0).
Abbreviations: Prob.-Probability; Pred.-Prediction; Funct.-Functional; Accur.-Accuracy; DDG–DDG value (kcal/mol); Del-Deleterious; N-Neutral; Dest- Destabilizing; P-
Pathogenic; UV-Unknown Variant.
doi:10.1371/journal.pone.0061302.t001
Figure 2. Results of functional assay of the studied missense
variants. Percentage of transcriptional activity was expressed as
percentage relative to the wild-type construct. Experiments were
performed in triplicate and normalized against the Renilla luciferase
internal control. Results are shown in bars: gray for controls and black
for variants.
doi:10.1371/journal.pone.0061302.g002
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within the a3-helix (Figure 3C). The substitution of this bulky
residue with a leucine likely destabilizes the folding of the domain,
analogously to experimentally confirmed observations of substitu-
tion by a cysteine [24,25]. G1770 is solvent-exposed and located
on a tight turn of the loop connecting the b1 strand with the a1
helix in the BRCT-C repeat (Figure 3D). It is highly conserved in
the Pfam alignment of the BRCT domain and probably confers to
the loop the necessary flexibility for phosphopeptide binding.
Substitution by a valine would expose a hydrophobic side chain
and confer rigidity to the loop, compromising the binding. In
contrast to the other mutations, this change may not affect folding.
Discussion
This study combined a functional BRCA1 assay and structural
analyses to predict whether specific missense variants in the
BRCA1 C-terminal region have pathological significance, con-
tributing to breast cancer risk. The variants selected were VUS
identified in a clinical scenario, which are located between amino
acid residues 1,396 and 1,863 of the full-length BRCA1 sequence
and include part of a coiled-coil domain (aa 1,364–1,437) and the
BRCT tandem domains (aa 1,646–1,863) (Figure 1). Notably, six
of the VUS (Q1409L, S1473P, E1586G, Y1703S, W1718L and
G1770V) had not been recorded in the locus-specific database for
Figure 3. Structural analysis of missense variants lying in the BRCA1 BRCT domain. Representation of the structure of the BRCT tandem
repeat from human BRCA1 in complex with a binding phosphopeptide (with the typical binding motif pSer-X-X-Phe, PDB ID 1t2v): in blue, the N-
terminal repeat (BRCT-N); in red, the C-terminal repeat (BRCT-C); in green, the linker region between the two; in cyan, the phosphopeptide with the
phosphoserine and the key binding residue Phe(+3); in, magenta the three mutated residues. Y1703 (A) forms a hydrogen bond with H1746 and is
adjacent to K1702, which binds directly to the pSer residue in the phosphopeptide. W1718 (B) fills the internal core and stabilizes the BRCT-N domain.
G1770 (C) gives the loop connecting the b1 strand with a1-helix in the BRCT-C repeat the necessary flexibility to form a tight turn, bringing the
residues N1774 and M1775 close to the phosphopeptide for interaction with the Phe(+3) key residue.
doi:10.1371/journal.pone.0061302.g003
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mutations in BRCA1 and BRCA2, BIC (Breast Cancer Information
Core database, http://research.nhgri.nih.gov/bic/) (Figure 1 and
Table 1).
The use of different in silico prediction algorithms gave
contradictory results for some of the variants (Table 1) making it
difficult to draw any clear conclusion. For example, there is a
striking difference between the results for three versions of
PolyPhen-2 as run from different sources; W1718L can yield
probabilities of pathogenicity of 0.086, 0.497 and 1.000, while the
probabilities for Q1409L, S1473P and E1586G range from values
below 0.2 to values above 0.95 in the different versions. If we tried
to order the variants according to their deleteriousness as
predicted from each of the algorithms, they would yield as many
orders as algorithms tested. In general terms, the two integrative
programs gave quite similar results, predicting a damaging effect
for one of the variants (G1770V) and a benign effect for four of
them (Q1409L, S1473P, E1586G and R1589H), while variants
Y1703S and W1718L were difficult to classify. Therefore,
attending to the results obtained in this study, we consider the
use of in silico programs not reliable enough to get an
approximation of the pathogenicity of a given VUS. In a recent
published paper by Li et al., the predictive power of Condel and
five individual methods (SIFT and PolyPhen2 among them) in
discriminating between pathogenic nsSNVs and other rare
nsSNVs, was examined [26]. Their results showed that the
predictive power of the combined Condel methodology is not
necessarily better than individual methods. Furthermore and in
agreement with our data, they show that correlations in the scores
between the predictive methods tested are weak or moderate. The
observed discrepancies among programs clearly support the need
of adding functional assay results in the process of classification of
VUS.
The TA assay in mammalian cells was performed as described
in previous studies [10]. This assay has been extensively validated,
proving to be extremely robust for variants located in the BRCT
domain [7,10,27,28]. In a previous study it has been benchmarked
using 14 pathogenic and 10 not pathogenic variants, showing high
sensitivity and specificity [28]. In this study two constructs
containing previously classified pathogenic variants (IARC Class
5), M1775R and Y1853X, were used as negative controls and a
construct with the wild-type BRCA1 C-terminal region was used
as a positive control. This assay clearly identified a functional
defect for three of the variants (Y1703S, W1718L and G1770V),
whereas the remaining variants gave results very similar to those of
the wild-type controls. It should be noted that residue W1718
appears to be highly prone to mutation, and although the
mutation studied here has never been reported, mutations
W1718S and W1718C have been described in HBOCS families;
in addition, a panel of assays including protease sensitivity,
phosphopeptide binding activity and specificity, as well as the TA
assay, revealed that both of these variants have strong functional
effects [28]. Both constitute large volume changes at a rigid
position in a rigid region that is part of the BRCT signature motif
WXXXS [29].
Next, to better interpret and understand the functional data
obtained, a structural analysis was performed for those VUS
located in the BRCT domains. This analysis was limited to the
BRCT domain as its structure has been solved [11], making it
possible to rationalize whether a given variant alters the domain
stability or the phosphopeptide-mediated binding to phosphory-
lated protein partners (Figure 3). The results indicated that the
three studied VUS in the BRCT domains seem to damage proper
BRCA1 structure. Interestingly, the experimental data obtained in
the TA assay support these structural predictions.
The pedigree structure of patients with these missense mutations
was, in general, not very informative for co-segregation analysis
(see Figure S1), either due to the lack of relatives with breast (or
ovarian) cancer or because no DNA samples for other relatives
were available. Nevertheless, it is worth noting that variant
Q1409L, which appears to have no effect on TA activity in the
present study, was found in a patient with a pathogenic mutation
in BRCA2 (c.5720_5723delCTCT), and although a small number
of carriers of two pathogenic mutations - one in BRCA1 and one in
BRCA2 - have been described worldwide this event has a very low
probability. In spite of this, and due to the fact that mutation
Q1409L is mapped in the BRCA1/PALB2 interaction region, it
would be worth to test if mutant L1409 is hampering the BRCA1/
PALB2 interaction [30]. Moreover, mutation G1770V, which
shows a clear impairment of TA activity, has been found in two
families of Moroccan origin presumed to be independent. In both
cases, patients suffer from breast or ovarian cancer at a very early
age of onset (27 and 30 years of age, respectively).
In summary, in a clinical context, extensive worldwide analysis
of BRCA1 has identified a large number of VUS, most of them
unique, which need to be classified for the purposes of diagnosis
and genetic counseling. By combining functional analysis and
structural rationalizations, this study shows that three BRCA1 VUS
(Y1703S, W1718L and G1770V) have profound functional impact
and may be pathogenic variants. By contrast, the other four
variants did not alter the function of BRCA1 in the TA assay and
should remain classified as VUS. The implementation of
combined approaches, such as the one presented here, is therefore
of considerable clinical relevance, especially in those cases where
co-segregation studies are not possible.
Supporting Information
Figure S1 Pedigrees of the families with the studied VUS.
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